Share on StockTwits
 

Charles River Laboratories International (NYSE:CRL) posted its quarterly earnings results on Wednesday. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.68 by $0.05, AnalystRatingsNetwork reports. The company had revenue of $289.20 million for the quarter, compared to the consensus estimate of $289.56 million. During the same quarter in the prior year, the company posted $0.64 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis.

A number of analysts have recently weighed in on CRL shares. Analysts at Sterne Agee raised their price target on shares of Charles River Laboratories International from $60.00 to $71.00 in a research note on Monday, January 13th. On the ratings front, analysts at Jefferies Group raised their price target on shares of Charles River Laboratories International from $57.00 to $64.00 in a research note on Tuesday, January 7th. Finally, analysts at Raymond James upgraded shares of Charles River Laboratories International from an “underperform” rating to a “market perform” rating in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $49.65.

Charles River Laboratories International (NYSE:CRL) opened at 57.99 on Wednesday. Charles River Laboratories International has a one year low of $39.25 and a one year high of $59.57. The stock’s 50-day moving average is $56.37 and its 200-day moving average is $50.47. The company has a market cap of $2.790 billion and a price-to-earnings ratio of 27.72.

Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.